LNA Santé stock
LNA.PAPARLNA Santé S.A., HealthcareISIN FR0004170017
55Score 55 out of 100, Neutral
Price and trend
41 / 100
Price history
+7.3% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 12% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 75).
The price is 28% below its 52-week high. Largest decline in 20 years: 75% (June 2017 to December 2023).
Chart figures for advanced users
- SMA 50$29.63
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$32.94
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$25.38
- The lowest closing price of the last twelve months.
- Resistance$40.45
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- LNA Santé S.A. belongs to the Medical (Care Facilities) industry (France) and, with a market value of $300.08M, is number 55 of 57 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.01B (up 13.1% year on year) and earnings of $26.76M (up 10.7%).
- For fiscal 2026, analysts expect on average revenue of $1.09B (up 7.7%) and adjusted earnings per share of $2.97 (up 13.9%).
Show more
- MEQIRI Score 55 out of 100 (Neutral): rank 331 of 702 in Healthcare, median 53.
- The P/E is 10.7 (Medical (Care Facilities) median 19.6, own median of recent years 17.1).
- Our model puts fair value at $58.02, with the price 50% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 232% of earnings over the last 12 months.Fundamentals 82
- Earnings per share growingUp 23.7% a year since 2020.Growth 61
- Modestly valuedP/E 10.7, Medical (Care Facilities) median 19.6, own median 17.1.Valuation 95
Weaknesses
- High debtDebt 2.74 times equity (latest quarter), Medical (Care Facilities) median 0.96.Stability 36
- Interest barely coveredOperating profit covers interest only 2 times.Stability 36
Its standout strengths are valuation and fundamentals, while stability and profitability hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Possible value trapIn our model the price counts as cheap below $44.63 and expensive above $82.89 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $62.47 (cash-flow model) and $53.58 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 11.7%. At 12.7% the fair value would be $54.94, at 10.7% it would be $61.88.
Possible value trap: looks cheap, but high risk.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 10.1% on the twelve months before. Revenue has grown strongly since 2006, at around 14% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 14%, operating 7%, net 3%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 31 Mar 2027in 138 days
- Last reported
- 16 Sep 2026EPS reported $1.35
Analyst estimates
Earnings estimates have barely changed since 7 Nov 2026.
- Earnings per share
- $2.970.0%
- Revenue
- $1.09B0.0%
- Earnings per share
- $3.630.0%
- Revenue
- $1.16B0.0%
MEQIRI has stored the estimates since 7 Nov 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at LNA Santé
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 55
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Strata Critical MedicalSRTA $515.38M46
- M1 KlinikenM12.DE $406.28M74
- Starling OncologySTLN $382.47M26
- Viemed HealthcareVMD $345.21M65
- AunaAUNA $338.24M42
- Community Health SystemsCYH $311.67M34
- MediclinMED.DE $284.23M61
- LIMES SchlossklinikenLIK.DE $194.79M73
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 6 Feb 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.